Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1583493 | 0.98 | CCNC (0.32) | CCNCCDK8CHRM2CHRM4CHRM1 | |
| SCHEMBL1583691 | 0.90 | IL4I1 (0.33) | HTR2CHTR2AHTR2B | |
| SCHEMBL749347 | 0.87 | HTR2C (0.36) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL18322272 | 0.85 | HTR2C (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL1583081 | 0.83 | NOS3 (0.39) | HTR2CHTR2AHTR2B | |
| SCHEMBL1161615 | 0.83 | NOS3 (0.39) | HTR2CHTR2AHTR2BHSD11B1 | |
| Hydrochloric Acid SCHEMBL1583544 | 0.81 | NOS3 (0.38) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL1583243 | 0.81 | NOS3 (0.38) | HTR2CHTR2AHTR2B | |
| SCHEMBL1583135 | 0.81 | POLB (0.39) | HTR2CHTR2AHTR2BHSD11B1 | |
| SCHEMBL1583741 | 0.81 | POLB (0.39) | HTR2CHTR2AHTR2BHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | claimed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | claimed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | claimed |
| WO-2025104411-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-05-22 | — | — | WO | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2695881-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-3002278-A1 | GUANIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20130143860-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143860-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | CCNC 2742/4885CDK8 3906/4885CHRM2 2260/4885 |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CCNC 680/4885CDK8 185/4885CHRM2 4082/4885 |
| US-20150203480-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | CCNC 2742/4885CDK8 3906/4885CHRM2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.